

First Foundation Puccini ALS Symposium

24th September 2025 Lausanne CHUV, Auditoire Yersin

An application for recognition as 0.5 day of continuing education is currently under review

Program

08:45 [Registration, In front of auditoire Yersin, CHUV, Lausanne](#)

09:00 **Welcoming**
Sylvain Lengacher, co-CEO GliaPharm SA

09:05 **Puccini Foundation presentation,**
Luca Regli and Filippo Donati, Puccini Foundation

Morning Session

09:15 **AAV-based gene therapy: application to motoneuron disease and next-generation vector design**
Bernard Schneider, EPFL

09:45 **Neuroimmune Motor Synapse Elimination in ALS**
Brian McCabe, EPFL

10:15 **TDP-43 regulation of microglial function**
Rosa Paolicelli, UNIL

10:45 [Coffee Break, Hall Auditorium, CHUV Lausanne](#)

11:05 **Metabolomic Approaches to Identify Diagnostic, Prognostic, and Therapeutic Monitoring Biomarkers in ALS**
Hélène Blasco, Université de Tours

11:35 **The Ying and Yang of Hydrogen sulphide in Amyotrophic Lateral Sclerosis**
Patrizia Longone, Fondazione Santa Lucia

12:05 [Lunch, Hall Auditorium, CHUV Lausanne](#)

Afternoon Session

13:35 **Challenges in ALS treatment - a clinician view**
Markus Weber, HOCH Health Ostschweiz

14:05 **Two Paths, One Disease: Understanding Sex Differences in ALS**
Adriano Chiò, University of Torino

14:35 **Swiss ALS Registry**
Jan Loosli, University Hospital Zurich

15:05 **Targeting hypometabolism in ALS : a new therapeutic approach**
Charles Finsterwald, CSO Gliapharm SA

15:35 **Closing remarks**

15:40 [Apero, Hall Auditorium, CHUV Lausanne](#)

*The Puccini Foundation
is recognized as a public
interest organization and
is tax-exempt*